Insider Selling: Bicycle Therapeutics plc (NASDAQ:BCYC) CEO Sells $62,730.16 in Stock

Bicycle Therapeutics plc (NASDAQ:BCYCGet Free Report) CEO Kevin Lee sold 3,194 shares of the firm’s stock in a transaction on Wednesday, July 3rd. The shares were sold at an average price of $19.64, for a total transaction of $62,730.16. Following the completion of the transaction, the chief executive officer now directly owns 384,076 shares in the company, valued at approximately $7,543,252.64. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Bicycle Therapeutics Price Performance

Shares of NASDAQ BCYC opened at $21.01 on Thursday. The company has a current ratio of 10.42, a quick ratio of 10.42 and a debt-to-equity ratio of 0.09. Bicycle Therapeutics plc has a twelve month low of $12.54 and a twelve month high of $27.50. The business has a 50 day simple moving average of $22.00 and a 200-day simple moving average of $21.68. The company has a market capitalization of $898.81 million, a price-to-earnings ratio of -4.72 and a beta of 0.93.

Bicycle Therapeutics (NASDAQ:BCYCGet Free Report) last posted its quarterly earnings results on Thursday, May 2nd. The company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($1.25) by $0.63. Bicycle Therapeutics had a negative net margin of 404.14% and a negative return on equity of 49.35%. The business had revenue of $19.53 million during the quarter, compared to analyst estimates of $6.06 million. Bicycle Therapeutics’s revenue for the quarter was up 298.9% compared to the same quarter last year. As a group, equities research analysts expect that Bicycle Therapeutics plc will post -4.44 earnings per share for the current year.

Institutional Trading of Bicycle Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in BCYC. Harbor Capital Advisors Inc. boosted its position in Bicycle Therapeutics by 27.2% during the 2nd quarter. Harbor Capital Advisors Inc. now owns 55,289 shares of the company’s stock valued at $1,119,000 after purchasing an additional 11,809 shares during the period. Baker BROS. Advisors LP boosted its holdings in shares of Bicycle Therapeutics by 176.1% during the first quarter. Baker BROS. Advisors LP now owns 4,942,823 shares of the company’s stock valued at $123,076,000 after acquiring an additional 3,152,433 shares during the period. Price T Rowe Associates Inc. MD grew its position in shares of Bicycle Therapeutics by 45.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 401,646 shares of the company’s stock worth $10,001,000 after acquiring an additional 124,809 shares during the last quarter. Westfield Capital Management Co. LP increased its holdings in shares of Bicycle Therapeutics by 13.3% in the 1st quarter. Westfield Capital Management Co. LP now owns 1,038,917 shares of the company’s stock worth $25,869,000 after acquiring an additional 121,613 shares during the period. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its stake in Bicycle Therapeutics by 12.8% during the 1st quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 883,105 shares of the company’s stock valued at $21,989,000 after purchasing an additional 100,107 shares during the period. 86.15% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

BCYC has been the subject of several analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $55.00 target price on shares of Bicycle Therapeutics in a research report on Friday, May 3rd. Needham & Company LLC reiterated a “buy” rating and issued a $43.00 price target on shares of Bicycle Therapeutics in a research note on Wednesday, April 10th. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $46.86.

View Our Latest Stock Report on BCYC

Bicycle Therapeutics Company Profile

(Get Free Report)

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.

Recommended Stories

Insider Buying and Selling by Quarter for Bicycle Therapeutics (NASDAQ:BCYC)

Receive News & Ratings for Bicycle Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicycle Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.